Company news

Vera Therapeutics, Inc. news in 2023

Vera Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

December 26, 2023

Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results

November 8, 2023

Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023

November 3, 2023

Vera Therapeutics Scheduled to Present at November Investor Conferences

October 29, 2023

Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting

October 12, 2023

Vera Therapeutics Scheduled to Present at September Investor Conferences

August 30, 2023

Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results

August 9, 2023

Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress

June 16, 2023

Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN

June 14, 2023

Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference

June 7, 2023

Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)

June 6, 2023

Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results

May 10, 2023

Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

May 3, 2023

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

March 27, 2023

Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

February 26, 2023

Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock

January 31, 2023

Vera Therapeutics Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy; Patients in the 150 mg Dose Group Achieved a Delta of 48% Versus Placebo in Mean Reduction in Proteinuria

January 29, 2023

Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)

January 24, 2023

Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

January 2, 2023

Decks in 2023